Efficacy and Durability of Ranibizumab (Lucentis®) in nAMD Patients 
Ranibizumab, commonly known as Lucentis®, has demonstrated remarkable efficacy and durability in patients with neovascular age-related macular degeneration (nAMD) in the RIVAL study1. This treatment has revolutionized the management of nAMD, offering hope for patients grappling with this degenerative condition.
Ranibizumab (Lucentis®) has been widely used for nAMD treatment in various countries, including Japan2. Its effectiveness is highlighted by its ability to significantly improve vision and quality of life3. The RIVAL study reported no significant difference between ranibizumab and aflibercept used for neovascular AMD4, further solidifying the standing of Ranibizumab (Lucentis®) in the field of nAMD treatment.
The durability of Ranibizumab (Lucentis®) is another factor that sets it apart. In the RIVAL study, patients treated with Ranibizumab (Lucentis®) showed consistent progress over an extended period1. Moreover, in another study, Ranibizumab (Lucentis®) demonstrated comparable significant decreases in Retinal Ganglion Cell Layer (RCGL) and Retinal Nerve Fiber Layer (RNFL) thickness compared to aflibercept and bevacizumab5, demonstrating the long-term safety and durability of this treatment.

Benefits of Treat-and-Extend Regimen with Ranibizumab (Lucentis®)
With the treat-and-extend regimen, patients receive injections of Ranibizumab (Lucentis®), only extending the interval between treatments when the disease activity is under control 6,7,8. This approach has proven successful in managing nAMD, with the RIVAL study showing significant improvements in patients following this regimen1.
In conclusion, Ranibizumab (Lucentis®) offers a promising option for nAMD patients. Its efficacy, durability, and the benefits of the treat-and-extend regimen make it a valuable treatment in the management of this degenerative condition. As we continue to explore and refine these treatments, the future looks brighter for those affected by nAMD.


References : 
  • JAMA Network: Kertes PJ, Galic IJ, Greve M, et al. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial . JAMA Ophthalmol. 2020;138(3):244–250. doi:10.1001/jamaophthalmol.2019.5540
  • Springer Link: Yanagi, Y., Takahashi, K., Iida, T. et al. Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan. Ophthalmol Ther 12, 2005–2021 (2023). https://doi.org/10.1007/s40123-023-00715-y
  • MDPI: Plyukhova, A.A.; Budzinskaya, M.V.; Starostin, K.M.; Rejdak, R.; Bucolo, C.; Reibaldi, M.; Toro, M.D. Comparative Safety of Bevacizumab, Ranibizumab, and Aflibercept for Treatment of Neovascular Age-Related Macular Degeneration (AMD): A Systematic Review and Network Meta-Analysis of Direct Comparative Studies. J. Clin. Med. 2020, 9, 1522. https://doi.org/10.3390/jcm9051522
  • Retinal Physician: Retinal Physician, Volume: 19, Issue: April 2022, page(s): 40-42. Retinal Physician - The Current Landscape of Intravitreal Treatments for Neovascular AMD
  • Wiley Online Library: Abdin, A.D., Suffo, S., Asi, F., Langenbucher, A. & Seitz, B. (2019) Intravitreal ranibizumab versus aflibercept following treat and extend protocol for neovascular age-related macular degeneration. Graefe's Archive for Clinical and Experimental Ophthalmology, 257, 1671–1677.
  • TandFOnline:Winfried Amoaku, Konstantinos Balaskas, Tomas Cudrnak, Louise Downey, Markus Groppe, Sajjad Mahmood, Hemal Mehta, Quresh Mohamed, Bushra Mushtaq, Philip Severn, Athanasios Vardarinos, Yit Yang & Saad Younis (2018) Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group, Clinical Ophthalmology, 12:, 1731-1740, DOI: 10.2147/OPTH.S174560
  • MDPI: Skelly, A.; Bezlyak, V.; Liew, G.; Kap, E.; Sagkriotis, A. Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD Patients. Vision 2019, 3, 41. https://doi.org/10.3390/vision3030041
  • TandFOnline: Ellie Bowditch, Eugenia Chu, Thomas Hong & Andrew A. Chang (2021) Treat and extend paradigm in management of neovascular age-related macular degeneration: current practice and future directions, Expert Review of Ophthalmology, 16:4, 267-286, DOI: 10.1080/17469899.2021.1933439
Do you find this content useful?: 
No votes yet

Medical Information Request


Ask Speakers